Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1998-8-14
|
| pubmed:abstractText |
The purpose of this study was to determine the effectiveness of second mobilization strategies in patients who yielded < 2.5 x 10(6) CD34+ PBSC/kg after initial mobilization. Repeat mobilization attempts were made with chemotherapy and G-CSF (n = 61) or G-CSF alone (n = 58) in patients who failed initial mobilization with chemotherapy and G-CSF (n = 92) or G-CSF alone (n = 27). A median of 0.27 x 10(6) CD34+ cells/kg per apheresis was collected after the second mobilization, compared with 0.16 with initial harvests (p = 0.0001). Forty-eight percent achieved a target CD34+ cell dose > or = 2.5 x 10(6)/kg when harvests from the first and second mobilizations were combined. Fifteen of 17 patients (88%) with > or = 1.5 x 10(6) CD34+ cells/kg harvested after first mobilization had > or = 2.5 x 10(6) CD34+ cells/kg collected when first and second harvests were combined, as compared with 42 of 102 (41%) achieving < 1.5 x 10(6) CD34+ cells/kg with first PBSC harvests (p = 0.0001). Second mobilizations with chemotherapy and G-CSF or G-CSF alone resulted in similar CD34+ cell yields. Toxicities of second mobilizations were comparable with those of first mobilizations. Seventy-nine patients (66%) received high-dose chemotherapy with PBSC support, with recovery of neutrophils and platelets in a median of 11 and 15 days, respectively. Transplant-related mortality was 4%, and event-free survival at 2 years was 0.34. It was concluded that second mobilization attempts in patients who fail to achieve > or = 2.5 x 10(6) CD34+ cells/kg on initial mobilization were successful in 48% of patients. G-CSF alone was as effective as chemotherapy plus G-CSF in mobilizing CD34+ cells and was associated with less morbidity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1061-6128
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
241-9
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:9621257-Adult,
pubmed-meshheading:9621257-Antigens, CD,
pubmed-meshheading:9621257-Antigens, CD34,
pubmed-meshheading:9621257-Antineoplastic Agents,
pubmed-meshheading:9621257-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9621257-Breast Neoplasms,
pubmed-meshheading:9621257-Combined Modality Therapy,
pubmed-meshheading:9621257-Cytapheresis,
pubmed-meshheading:9621257-Female,
pubmed-meshheading:9621257-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9621257-Hematopoietic Stem Cells,
pubmed-meshheading:9621257-Hodgkin Disease,
pubmed-meshheading:9621257-Humans,
pubmed-meshheading:9621257-Lymphoma,
pubmed-meshheading:9621257-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9621257-Male,
pubmed-meshheading:9621257-Melphalan,
pubmed-meshheading:9621257-Middle Aged,
pubmed-meshheading:9621257-Multiple Myeloma,
pubmed-meshheading:9621257-Neoplasm Staging
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields.
|
| pubmed:affiliation |
Clinical Research Division of Response Oncology, Inc., Memphis, TN 38117, USA.
|
| pubmed:publicationType |
Journal Article
|